Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of cholestyramine/colesevelam and probenecid on PFAS elimination in highly exposed healthy adults
2021-005865-42Phase 2Completed
- Sponsor
- University of Gothenburg
- Start
- Mar 2022
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of cholestyramine, colesevelam and probenecid, sponsored by University of Gothenburg. Primary endpoints: Change of PFAS in faeces during treatment and Change of PFAS in urine during treatment. Started Mar 2022; status: completed.
02
Drugs
cholestyraminecolesevelamprobenecid
Beyond the preview
Go deeper on 2021-005865-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005865-42.